Heparin-Natrium Leo (Heparin Sodium)

Heparin-Natrium Leo is indicated for several antithrombotic purposes in clinical practice.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation in extracorporeal circuits such as dialysis or cardiopulmonary bypass.
• Management of acute coronary syndromes, including unstable angina and myocardial infarction.
• Peri‑operative thromboprophylaxis in patients undergoing major surgery.
• Adjunct therapy in patients with atrial fibrillation at risk of embolic events.

Heparin-Natrium Leo may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common

• Minor bleeding at injection sites or mucosal surfaces.
• Mild thrombocytopenia without clinical sequelae.
• Localized bruising or hematoma formation.
• Transient elevation of liver enzymes.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Spinal or epidural hematoma following neuraxial procedures.
• Severe allergic reactions such as anaphylaxis.
• Adrenal gland hemorrhage.

When prescribing Heparin‑Natrium Leo, clinicians should observe several safety considerations.

• Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels to maintain therapeutic range.
• Assess patient history for active bleeding, recent surgery, or trauma before initiation.
• Use caution in individuals with renal or hepatic impairment, adjusting dose as needed.
• Avoid use in patients with known heparin‑induced thrombocytopenia or a history of severe allergic reactions to heparin.
• Consider potential risks during pregnancy; data are limited.
• Evaluate concomitant use of other anticoagulants or antiplatelet agents for additive bleeding risk.

Heparin‑Natrium Leo can interact with several drug classes, influencing bleeding risk or anticoagulant effect.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) or thrombolytic agents.
• Combination with antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor without careful monitoring.
• Simultaneous administration of high‑dose NSAIDs that impair platelet function.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at low doses.
• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents.
• Corticosteroids, which may increase gastrointestinal bleeding risk.
• Certain antibiotics (e.g., vancomycin, linezolid) that can affect coagulation parameters.